OMIX

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

OMIX001599

1Summary
Title First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
Description Abstract publication for ESMO 2022
Organism Homo sapiens
Data Type Other Type of Clinical information
Data Accessibility Controlled-access
BioProject PRJCA011148
Release Date 2022-09-09
Submitter shun Lu (shunlu_shchest@sina.com)
Organization Shanghai Chest Hospital
Submission Date 2022-08-11
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download Times Download
OMIX001599-02 Analysis result 1 Other Type of Clinical information 109.0 KB pdf 0 Controlled

Request for this Data View All Released Data of OMIX